• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RPRX

    Royalty Pharma plc

    Subscribe to $RPRX
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: royaltypharma.com

    Peers

    $BHVN

    Recent Analyst Ratings for Royalty Pharma plc

    DatePrice TargetRatingAnalyst
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    4/6/2022$48.00Overweight
    Morgan Stanley
    10/29/2021$50.00Neutral → Buy
    Citigroup
    8/16/2021$51.00 → $46.00Equal-Weight
    Morgan Stanley
    7/30/2021$50.00Buy
    Tigress Financial
    See more ratings

    Royalty Pharma plc Financials

    Live finance-specific insights

    See more
    • Royalty Pharma Reports First Quarter 2025 Results

      Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Guided by our dynamic capital allocat

      5/8/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Declares Second Quarter 2025 Dividend

      NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royal

      4/21/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharm

      4/17/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Upcoming Investor Day

      NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company's plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. Additional details will follow closer to the event. The live webcast may be accessed from the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/. Th

      3/27/25 8:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces R&D Funding Collaboration With Biogen

      NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). "We are excited to collaborate with Biogen on litifilimab," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Royalty Pharma offers tailored, win-win funding solutions for promising therapies in areas of high unmet medical need. Litifilimab has the potenti

      2/12/25 6:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Reports Q4 and Full Year 2024 Results

      Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024Full year 2025 guidance: Portfolio Receipts expected to be $2,900 to $3,050 million excluding future transactions NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts. "We had an incredibly successful 2024, delivering double-digit growth in Royalty Receipts, which was significantly above our initi

      2/11/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

      Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The company generated an attractive

      1/29/25 9:00:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

      NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Ro

      1/28/25 4:15:21 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

      2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for pelacarsen Royalty Pharma to benefit from new product launches in 2025, including Servier's Voranigo, Bristol Myers Squibb's Cobenfy, Ascendis' Yorvipath, Syndax and Incyte's Niktimvo and Geron's Rytelo NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta

      1/10/25 7:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

      Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsSimplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of shares intended to be repurchased in 2025 subject to market conditionsMaintain significant capacity for new royalty transactions and remain committed to mid-single digit percentage annual dividend grow

      1/10/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Royalty Pharma plc SEC Filings

    See more
    • SEC Form 10-Q filed by Royalty Pharma plc

      10-Q - Royalty Pharma plc (0001802768) (Filer)

      5/8/25 9:14:25 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma plc filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Royalty Pharma plc (0001802768) (Filer)

      5/8/25 7:31:50 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Royalty Pharma plc

      DEFA14A - Royalty Pharma plc (0001802768) (Filer)

      4/11/25 9:15:25 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Royalty Pharma plc

      8-K - Royalty Pharma plc (0001802768) (Filer)

      4/11/25 8:53:01 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFM14A filed by Royalty Pharma plc

      DEFM14A - Royalty Pharma plc (0001802768) (Filer)

      4/11/25 8:45:41 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Royalty Pharma plc

      DEFA14A - Royalty Pharma plc (0001802768) (Filer)

      4/10/25 4:17:15 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Royalty Pharma plc

      8-K - Royalty Pharma plc (0001802768) (Filer)

      4/10/25 4:06:02 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Royalty Pharma plc

      DEFA14A - Royalty Pharma plc (0001802768) (Filer)

      3/5/25 5:25:14 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Royalty Pharma plc

      SCHEDULE 13D/A - Royalty Pharma plc (0001802768) (Subject)

      2/21/25 4:30:18 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PREM14A filed by Royalty Pharma plc

      PREM14A - Royalty Pharma plc (0001802768) (Filer)

      2/13/25 6:03:51 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Royalty Pharma plc Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      11/8/24 3:15:49 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

      SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

      7/29/24 4:30:11 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/13/24 10:17:30 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/9/24 3:13:26 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/9/24 9:49:30 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/13/23 4:53:44 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/10/23 3:21:33 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/9/23 12:31:05 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/9/23 11:06:35 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Royalty Pharma plc (Amendment)

      SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

      10/4/22 4:30:28 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Royalty Pharma plc Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Royalty Pharma plc Leadership Updates

    Live Leadership Updates

    See more
    • Royalty Pharma downgraded by UBS with a new price target

      UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00

      6/3/24 9:17:33 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS resumed coverage on Royalty Pharma with a new price target

      UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00

      6/14/22 7:27:46 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Royalty Pharma with a new price target

      Scotiabank initiated coverage of Royalty Pharma with a rating of Sector Outperform and set a new price target of $53.00

      5/13/22 7:24:42 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Royalty Pharma with a new price target

      Goldman initiated coverage of Royalty Pharma with a rating of Buy and set a new price target of $56.00

      4/27/22 6:14:09 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma upgraded by JP Morgan with a new price target

      JP Morgan upgraded Royalty Pharma from Neutral to Overweight and set a new price target of $50.00

      4/14/22 7:22:45 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley resumed coverage on Royalty Pharma with a new price target

      Morgan Stanley resumed coverage of Royalty Pharma with a rating of Overweight and set a new price target of $48.00

      4/6/22 9:01:11 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma upgraded by Citigroup with a new price target

      Citigroup upgraded Royalty Pharma from Neutral to Buy and set a new price target of $50.00

      10/29/21 7:26:16 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Royalty Pharma with a new price target

      Morgan Stanley reiterated coverage of Royalty Pharma with a rating of Equal-Weight and set a new price target of $46.00 from $51.00 previously

      8/16/21 9:05:21 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tigress Financial initiated coverage on Royalty Pharma with a new price target

      Tigress Financial initiated coverage of Royalty Pharma with a rating of Buy and set a new price target of $50.00

      7/30/21 10:09:23 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

      4/8/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

      NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg

      7/24/24 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

      NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody

      9/21/23 8:25:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments

      NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman. Ashwin joins Royalty Pharma from Morgan Stanley where he was a Managing Director and Head of West Coast Biotechnology Investment Banking. In his nearly two decade career, Ashwin has been involved in some of the most significant mergers and acquisitions transactions and partnerships in the biotechnology industry. In addition, he has advised clients on numerous capital raising events, including initial

      3/1/23 8:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

      Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company. "Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company's growth as CEO," said Dr. Beetham. "With the recent progress toward a European approval of Cibus' proprietary precision gene-editing technology, as well as other recent Cibus commercial announcements, this manageme

      10/7/21 9:00:00 AM ET
      $FGEN
      $ITCI
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director RP Management, LLC

      NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry A. Fernandez as Lead Independent Director. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc. Mr. Fernandez will continue to serve on the Audit Committee of Royalty Pharma plc. “We are further strengthening the governance of Royalty Pharma with this new key role," stated Pablo Legorreta, founder, CEO and Chairman of Royalty Pharma. “Henry has a record of exceptional leadership having led MSCI from a nascent index business to a leading global provider of critical decisio

      3/30/21 8:00:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces 13% Dividend Increase

      NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A share, reflecting a 13% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 15, 2021, to shareholders of record at the close of business on February 19, 2021. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-prof

      1/8/21 8:00:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Royalty Pharma plc Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Royalty Pharma Reports First Quarter 2025 Results

      Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Guided by our dynamic capital allocat

      5/8/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)

      Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion and diversification of manufacturing footprint further ensures stable and sustainable supply to meet the anticipated growth in global demand for ADSTILADRIN Milestone prompts final $200 million payment from Royalty Pharma Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating gene therapy ADSTILADRIN® (nadofaragene firadenovec-vncg). The approval expands Ferring's manufacturing capabilities

      4/24/25 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Declares Second Quarter 2025 Dividend

      NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royal

      4/21/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharm

      4/17/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

      4/8/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Upcoming Investor Day

      NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company's plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. Additional details will follow closer to the event. The live webcast may be accessed from the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/. Th

      3/27/25 8:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference

      NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and m

      2/27/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces R&D Funding Collaboration With Biogen

      NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). "We are excited to collaborate with Biogen on litifilimab," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Royalty Pharma offers tailored, win-win funding solutions for promising therapies in areas of high unmet medical need. Litifilimab has the potenti

      2/12/25 6:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Reports Q4 and Full Year 2024 Results

      Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024Full year 2025 guidance: Portfolio Receipts expected to be $2,900 to $3,050 million excluding future transactions NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts. "We had an incredibly successful 2024, delivering double-digit growth in Royalty Receipts, which was significantly above our initi

      2/11/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

      Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The company generated an attractive

      1/29/25 9:00:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Royalty Pharma plc Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, Chairman of the Board Legorreta Pablo G. was granted 288,352 units of Class A Ordinary Shares, increasing direct ownership by 452% to 352,147 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:18:28 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Investments & CLO Lloyd George W. was granted 48,646 units of Class A Ordinary Shares (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:15:40 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Vice Chairman Hite Christopher was granted 48,646 units of Class A Ordinary Shares (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:14:15 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & CFO Coyne Terrance P. was granted 48,646 units of Class A Ordinary Shares (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:10:41 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Research & Investments Urist Marshall was granted 36,484 units of Class A Ordinary Shares, increasing direct ownership by 78% to 83,151 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:07:47 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Coric Vlad was granted 3,184 units of Class A Ordinary Shares (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      4/21/25 5:43:06 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 3 filed by new insider Coric Vlad

      3/A - Royalty Pharma plc (0001802768) (Issuer)

      4/21/25 5:40:27 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Royalty Pharma Plc

      3 - Royalty Pharma plc (0001802768) (Reporting)

      4/21/25 5:18:50 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bassler Bonnie L was granted 1,141 units of Class A Ordinary Shares, increasing direct ownership by 2% to 62,440 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      4/1/25 5:46:45 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fernandez Henry A was granted 1,141 units of Class A Ordinary Shares, increasing direct ownership by 2% to 56,646 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      4/1/25 5:45:32 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care